

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

COVID-19 and Pulmonology in the XXI century: Challenge or Opportunity?


- What is the **health emergency** specifically, and who exactly does it affect?
Which groups are **behind** this health emergency?
- **Healthcare systems** were overwhelmed to the point of collapse both in terms of **physical space** and **their ability** to treat patients to the expected quality standards.
- In the first wave of this new entity, the **most dominant** clinical manifestation has been severe **life threatening respiratory involvement**.
- The demand for **ICU admission exceeded capacity** in the first weeks, so **existing resources** had to be expanded with the support of respiratory departments.

- At this point, respiratory medicine departments with their experience in non-invasive mechanical ventilation (NIMV) began to **play key role**.
- NIV offered a significant number of patients **relief from their respiratory failure**, while for others it provided life support while awaiting admission to an ICU.
- It is up to us to take the maximum benefit from the lessons learned by the pandemic in order to develop and affirm the position and relevance of pulmonology and respiratory departments in our society.
- As a scientific society, it is our responsibility to call on the health authorities to provide us with the **material and human resources** we need to carry out our professional work to the required **standards of care** to minimize the consequences of this disease and to continue to serve patients with respiratory diseases.

- Among **patients hospitalized** with coronavirus disease 2019 (COVID-19), up to **one-quarter** require intensive care unit (ICU) admission.
- Among those who are critically ill, profound acute hypoxemic respiratory failure from **ARDS** is the dominant finding. **Hypercapnia** is rare. **Fevers** tend to wax and wane during ICU admission. The **need for mechanical ventilation** in those who are critically ill is high ranging from **30 to 100** percent.
- Length of intensive care unit (ICU) stay appears to be **one to two weeks** or longer
- Common complications of COVID-19-related **ARDS** include acute kidney injury (**AKI**), elevated **liver enzymes**, and **cardiac injury** including cardiomyopathy, pericarditis, pericardial effusion, arrhythmia, and sudden cardiac death.
- Data on the risk of **secondary bacterial pneumonia** are limited, but it does not appear to be a major feature of COVID-19.

➤ **Neurologic complications** in critically ill patients are common, especially **delirium** or **encephalopathy** which manifests with prominent **agitation** and **confusion** along with corticospinal tract signs(hyperreflexia).

➤ **Chest radiographs** may be normal in early or mild disease. **Common abnormal** radiograph findings were **consolidation** and **ground glass** opacities, with bilateral, peripheral, and lower lung zone distributions; lung involvement increased over the course of illness, with a peak in **severity at 10 to 12** days after symptom onset.





Chest CT

- Chest computed tomography (CT) can be **more sensitive** than **chest radiograph** and some chest CT findings can be **characteristic** of COVID-19.
- We **not using** chest CT **for screening** or **diagnosis** of COVID-19 and recommends **reserving it** for hospitalized patients .
- Chest CT in patients with COVID-19 most commonly demonstrates:
 - Ground-glass opacifications
 - Ground-glass opacifications with mixed consolidation
 - Adjacent pleural thickening
 - Interlobular septal thickening
 - Air bronchograms

- Chest **CT abnormalities** in COVID-19 are **often bilateral**, have a **peripheral distribution**, and involve the **lower lobes**.
- Chest CT may be normal **soon after the onset** of symptoms, with abnormalities more likely to develop **over the course** of illness .
- Among patients who clinically improve, **resolution of radiographic** abnormalities may lag behind improvements in **fever and hypoxia**.

Lung imaging is utilized:

- As a part of patients with COVID-19 infection **particularly when** the PCR approach is not available.
- Could be considered as an **additional evaluation** beside lab testing for patients with critical conditions.
- Chest X-ray has **low precision**, especially in early phase and minimal symptoms.
- In patients with cough, chilling, sore throat with dyspnea and hypoxia (RR>24 & Spo2<93)
- In **high risk patients** with leukocytosis or leukopenia and fever, CT-scan should be carried out.

- lung imaging is **not indicated for screening** of COVID-19 .
- Generally, if *severity of lung involvement* is high in CT-imaging, *hypoxemic intensity* will be higher. However, necessarily this correlation is **not linear**. This is a strong reason for not using CT-scan in patients with *minimal symptoms and signs*.





❖ Indication of repeating CT-scan:

Persistent hypoxemia without O₂ after two weeks

progression of hypoxemia after two weeks of treatment

Abnormal PFT 4-weeks after the treatment

Candidates of chemotherapy and Immunosuppressive agent therapy after convalescence period.



Covid19 specific therapy

- Dexamethazon
- Remdesivir
- Convalescent plasma and other antibody-based therapies
- Il-6 pathway inhibitor
- Hydroxychloroquine/chloroquine
- Others: favipravir-interferons-azithromycin&HCQ-ivermectin-colchicine-famotidine-sofosbuvir.....

THE CHALLENGE OF MANAGING COVID-19 ASSOCIATED PULMONARY ASPERGILLOSIS

- Two immunosuppressant agents, **corticosteroids** and **tocilizumab**, were widely used.
- The blockade of IL-6 might be a **very specific risk factor** for the development of CAPA.
- It is known that corticosteroids can impair a **specific form of phagocytosis** called LC3-associated phagocytosis, which is essential for host defense against aspergillosis.
- Dexamethasone was found to reduce mortality by **one-third** in seriously ill COVID-19 patients on ventilator support.

COVID-19 and pulmonary rehabilitation

- The **follow-up** is currently the **new challenge** as it was in the beginning for ICUs. Indeed, it is **not clear** if COVID-19 will leave **permanent lung and/or physical damage** and, if so, to what extent.
- **Persisting limitations** in **respiratory function** and **gas exchange** will likely be more pronounced in the subgroup of **ICU survivors**.
- How can we identify patients **with an impaired health condition** after COVID-19 and how can the **follow-up be organised?**
- Some patients with a **poor health condition**, specifically those with an **extended long stay in the ICU**, will be discharged immediately for **inpatient rehabilitation**.

Pulmonary embolism in COVID-19

- The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has raised **new challenges** in the diagnosis of pulmonary embolism.
- Patients with coronavirus disease 2019 (COVID-19) are at **increased risk** of developing venous thromboembolism, but symptoms of COVID-19 and PE may overlap, which makes it difficult to identify those with a higher likelihood of PE.
- The authors report that they “identified a **D-dimer cut-off value of 2590 ng·ml** to best predict occurrence of PE.
- Particular attention should be paid to search for **potential PE** in patients with a D-dimer level above 2590 ng·ml.
- **D-dimer** testing is insufficiently accurate to be used as a standalone test in the diagnosis of PE.

- In patients with a low D-dimer (usually, a **threshold of 500 or 1000 ng·ml** is applied), PE can safely be ruled-out without CTPA. In contrast, in those with a D-dimer above the threshold, subsequent CTPA needs to be performed.
- Whether similar D-dimer thresholds can be applied **in COVID-19** patients suspected of PE is **unknown**, because COVID-19 triggers a hyperinflammatory state with endothelial activation and high D-dimer levels.

سپاس از حسن توجهتان

